9.6 mg intranasal carbetocin ( DrugBank: Carbetocin )


1 disease
IDDisease name (Link within this page)Number of trials
193Prader-Willi syndrome1

193. Prader-Willi syndrome


Clinical trials : 111 Drugs : 120 - (DrugBank : 30) / Drug target genes : 51 - Drug target pathways : 103
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03649477
(ClinicalTrials.gov)
November 20, 201824/8/2018Phase 3 Study of Intranasal Carbetocin (LV-101) in Patients With Prader-Willi SyndromePhase 3, Randomized, Double-Blind, Placebo-Controlled, 8-week Clinical Study to Assess the Efficacy, Safety, and Tolerability, of Intranasal Carbetocin (LV-101) in Prader-Willi Syndrome (PWS) With Long Term Follow-Up (CARE-PWS)Prader-Willi SyndromeDrug: 3.2 mg intranasal carbetocin;Drug: 9.6 mg intranasal carbetocin;Drug: placeboLevo Therapeutics, Inc.NULLActive, not recruiting7 Years18 YearsAll130Phase 3United States;Australia;Canada